text size A A A

Stryker OP-1/BMP-7

OP-1 products are approved under an HDE for trauma and spine use
OP-1 products are approved under an HDE for trauma and spine use
OP-1 products are approved under an HDE for trauma and spine use
An Overview of OP-1 Products

OP-1 Putty and OP-1 Implant are currently approved in the United States under Humanitarian Device Exemptions (HDE) for revision posterolateral lumbar spine fusion and for the treatment of long bone nonunion fractures, respectively. OP-1 Implant is approved in 28 additional countries, including Australia, Canada, and the European Union. Approximately 40,000 patients have been treated globally with OP-1 products.

The active ingredient in OP-1 products is recombinant human bone morphogenetic protein-7 (rhBMP-7 or Osteogenic Protein 1), a recombinant version of a naturally occurring growth factor that belongs to a class of proteins known as bone morphogenetic proteins (BMPs) that are the only known proteins capable of inducing the formation of new bone. Stryker’s recombinant biotechnology process allows human OP-1/BMP-7 to be produced and delivered on a purified Type I bone collagen carrier that provides an osteoconductive scaffold on which new bone can grow.



Features & Benefits
OP-1, which has been in development for over 20 years, is the subject of 350 papers supporting its use in approved indications. As an alternative to autograft, OP-1 products have the potential to reduce:
  • Operating room time
  • Blood loss
  • Hospital stays
  • Osteomyelitis (infections)
  • Donor site morbidity